{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:39:18Z","timestamp":1761766758049,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.acvd.2020.07.001","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T08:50:54Z","timestamp":1597654254000},"page":"572-578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9596-5347","authenticated-orcid":false,"given":"Bernard I.","family":"L\u00e9vy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Fauvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2020.07.001_bib0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0235","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1471-4159.2008.05723.x","article-title":"Angiotensin-converting enzyme 2 in the brain: properties and future directions","volume":"107","author":"Xia","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.acvd.2020.07.001_bib0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ki.2012.127","article-title":"Podocyte ACE2 protects against diabetic nephropathy","volume":"82","author":"Harris","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.acvd.2020.07.001_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2162","article-title":"The emerging role of ACE2 in physiology and disease","volume":"212","author":"Hamming","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0250","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/ATVBAHA.120.314558","article-title":"Overcoming barriers: the endothelium as a linchpin of coronavirus disease 2019 pathogenesis?","volume":"40","author":"Gustafson","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0255","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(20)31129-6","article-title":"Kawasaki-like disease: emerging complication during the COVID-19 pandemic","volume":"395","author":"Viner","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.acvd.2020.07.001_bib0260","doi-asserted-by":"crossref","first-page":"271e8","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.acvd.2020.07.001_bib0265","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.acvd.2020.07.001_bib0270","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2020.07.001_bib0275","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.HYP.0000251865.35728.2f","article-title":"Angiotensin-(1-7) through receptor MAS mediates endothelial nitric oxide synthase activation via Akt-dependent pathways","volume":"49","author":"Sampaio","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.07.001_bib0280","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.acvd.2012.02.010","article-title":"Three key proteases\u2013angiotensin-I-converting enzyme (ACE), ACE2 and renin\u2013within and beyond the renin\u2013angiotensin system","volume":"105","author":"Guang","year":"2012","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2020.07.001_bib0285","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2020.07.001_bib0290","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2020.07.001_bib0295","first-page":"17","article-title":"Circulating ACE2 activity correlates with cardiovascular disease development","author":"Uri","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.acvd.2020.07.001_bib0300","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/HJH.0b013e32834f04b6","article-title":"Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications","volume":"30","author":"Soro-Paavonen","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.acvd.2020.07.001_bib0305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00380-016-0877-z","article-title":"Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalisation","volume":"32","author":"Hisatake","year":"2017","journal-title":"Heart Vessels"},{"key":"10.1016\/j.acvd.2020.07.001_bib0310","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"Sama","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2020.07.001_bib0315","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin\u2013angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","volume":"116","author":"Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.acvd.2020.07.001_bib0320","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2020.07.001_bib0325","doi-asserted-by":"crossref","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","article-title":"Localisation of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan","volume":"296","author":"Soler","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0330","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.yjmcc.2016.05.012","article-title":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-MAS axes in pressure overload-induced cardiac remodelling in male mice","volume":"97","author":"Wang","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0335","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalisation and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.07.001_bib0340","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.acvd.2020.07.001_bib0345","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41569-020-0368-x","article-title":"Interaction between RAAS inhibitors and ACE2 in the context of COVID-19","volume":"17","author":"Mourad","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0350","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41569-020-0387-7","article-title":"Mechanisms by which angiotensin-receptor blockers increase ACE2 levels","volume":"17","author":"Ferrario","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0355","doi-asserted-by":"crossref","first-page":"H1351","DOI":"10.1152\/ajpheart.01186.2004","article-title":"Effects of spironolactone and eprosartan on cardiac remodelling and angiotensin-converting enzyme isoforms in rats with experimental heart failure","volume":"289","author":"Karram","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0360","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000187500.24964.7A","article-title":"Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients","volume":"97","author":"Keidar","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.acvd.2020.07.001_bib0365","first-page":"891","article-title":"Aliskiren inhibits angiotensin II\/angiotensin 1-7(Ang II\/Ang1-7) signal pathway in rats with diabetic nephropathy","volume":"34","author":"Ding","year":"2018","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.acvd.2020.07.001_bib0370","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fphys.2016.00299","article-title":"Aliskiren administration during early postnatal life sex-specifically alleviates hypertension programmed by maternal high fructose consumption","volume":"7","author":"Hsu","year":"2016","journal-title":"Front Physiol"},{"key":"10.1016\/j.acvd.2020.07.001_bib0375","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.07.001_bib0380","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.acvd.2020.07.001_bib0385","doi-asserted-by":"crossref","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumour necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.acvd.2020.07.001_bib0390","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","volume":"81","author":"Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.acvd.2020.07.001_bib0395","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.acvd.2020.07.001_bib0400","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMe2012924","article-title":"Inhibitors of the Renin-Angiotensin-Aldosterone System and COVID-19","volume":"382","author":"Jarcho","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.07.001_bib0405","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin\u2013Angiotensin\u2013Aldosterone system blockers and the risk of COVID-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.07.001_bib0410","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-Angiotensin-Aldosterone system inhibitors and risk of COVID-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2020.07.001_bib0415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: a single-centre retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"year":"2020","series-title":"Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for patients with COVID-19 (APN01-COVID-19)","key":"10.1016\/j.acvd.2020.07.001_bib0420"},{"key":"10.1016\/j.acvd.2020.07.001_bib0425","doi-asserted-by":"crossref","first-page":"19840","DOI":"10.1038\/srep19840","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.acvd.2020.07.001_bib0430","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1038\/ncomms4594","article-title":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"year":"2020","series-title":"Losartan for patients with COVID-19 not requiring hospitalisation","key":"10.1016\/j.acvd.2020.07.001_bib0435"},{"year":"2020","series-title":"Losartan for patients with COVID-19 requiring hospitalisation","key":"10.1016\/j.acvd.2020.07.001_bib0440"},{"key":"10.1016\/j.acvd.2020.07.001_bib0445","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.120.15370","article-title":"Controversial relationship between renin-angiotensin system inhibitors and severity of COVID-19: announcing a large multicentre case-control study in Italy","author":"Di Castelnuovo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.acvd.2020.07.001_bib0450","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","article-title":"COVID-19 and cardiovascular disease","volume":"141","author":"Clerkin","year":"2020","journal-title":"Circulation"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213620301571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213620301571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:46:42Z","timestamp":1761745602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213620301571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":45,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1875213620301571"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2020.07.001","relation":{},"ISSN":["1875-2136"],"issn-type":[{"type":"print","value":"1875-2136"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2020.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}